GLP-1 drugs linked to significantly higher risk of hair loss – Earth.com
08-10-2026
Popular weight loss drugs linked to a higher risk of hair loss
ByEric Ralls
Earth.com staff writer
A side effect that never showed up in the big trials has been turning up in Reddit threads and clinic visits for years. Researchers finally went looking for it in the medical records of nearly 24,000 people
You notice it in the shower first – more hair circling the drain, then more in the brush, until you’re checking the pillow each morning like a detective at a crime scene
It’s not painful, and it won’t land you in the hospital. But hair loss can be very alarming
For the past few years, people taking Ozempic, Wegovy and Mounjaro have been comparing notes about exactly this
Their doctors mostly had to shrug, because the evidence was a pile of anecdotes with no way to test it
Linking weight loss drugs and hair loss
Hair loss never surfaced as a headline problem in the trials that got these drugs approved
Instead, it showed up later, from the bottom up: scattered case reports, patient forums, and complaints people filed with the FDA, which said back in 2023 that it was taking a look
The trouble with anecdotes, though, is that they have no control group. Plenty of people lose hair for plenty of reasons, and plenty of people take these drugs. So how do you tell a real signal from noise?
A team at the University of Pennsylvania decided to build the missing comparison. Writing in The BMJ, the team – led by first author Huilin Tang and senior author Yong Chen, with Penn dermatologist George Cotsarelis – used a method called target trial emulation
In plain terms, nobody is going to randomly assign thousands of patients to Ozempic just to watch their hairlines
Instead, you comb through years of real medical records and construct something that behaves as much like a trial as the data will allow
What the records showed
They pulled electronic health records from Penn Medicine, a large academic health system covering the Philadelphia area, Delaware and southern New Jersey
Everyone in the analysis was an adult with type 2 diabetes who started a new medication between January 2019 and September 2024. The researchers excluded anyone with an existing hair loss diagnosis
Then came the comparisons. About 12,000 people starting a GLP-1 drug were set against roughly 15,200 starting SGLT-2 inhibitors, a different class of diabetes medication
A second matchup put about 12,000 GLP-1 starters against 11,233 people on DPP-4 inhibitors
The groups weren’t identical to begin with. GLP-1 patients skewed younger, with a mean age of 58 against 65 and 67 in the comparison groups. They carried more weight, with an average body mass index of 36.2 versus roughly 32 and 31
So the researchers adjusted for age, sex, ethnicity, existing conditions, other medications and BMI. Even after that, GLP-1 users turned out 37% more likely than SGLT-2 users to receive a hair loss diagnosis, and 68% more likely than DPP-4 users
Big percentage, small numbers
Here’s where a headline can mislead you. A 68% jump sounds like something is seriously wrong. Check the raw rates and the picture changes shape
Hair loss showed up at about 6.91 cases per 1,000 person-years among GLP-1 users, compared with 5.04 among SGLT-2 users and 3.89 among DPP-4 users
Translated into something you can picture: roughly seven people out of every thousand per year, against four or five on the other drugs
Dr. Marie Spreckley is a weight management researcher at the University of Cambridge who was not involved in the work
“In practical terms, this means around two to three additional clinically recorded cases of hair loss per 1,000 person-years of treatment compared with the alternative diabetes medications,” said Dr. Spreckley
What may explain the hair loss
If a drug were directly poisoning hair follicles, you’d expect every flavor of hair loss to creep upward together. That isn’t what happened
Almost all of the increase involved non-scarring alopecia, the type where the follicle survives and hair can grow back: 53% higher against SGLT-2 users, 72% higher against DPP-4 users
Scarring hair loss, the permanent kind, showed no clear link. Neither did alopecia areata, the autoimmune version that leaves round bald patches
Most cases appeared inside the first year of treatment, which is a clue, since the first year is when the weight comes off fastest
“Our findings extend previous anecdotal safety signals and provide more systematic evidence to inform clinical awareness of this potential adverse effect,” the authors conclude
Think of your scalp as a factory running staggered shifts. Each follicle cycles independently between growing and resting, which is why you shed a bit every day and never notice
Put the body under real metabolic stress and a big batch of follicles clock off at once. Weeks later, they all let go together, and suddenly the drain looks alarming
That pattern has a name, telogen effluvium, and rapid weight loss is one of its oldest known triggers. Eating a lot less can also leave you short on iron and zinc, both of which the hair growth cycle depends on
The authors note that hormonal changes may play a part too, though they’re clear that scientists still need to pin down the mechanism
So the drug may be less the culprit than the messenger. It works, you lose weight quickly, and your hair reacts to the weight loss
Where the evidence stops
This is an observational study, so it cannot prove cause. “As with all observational studies, it cannot establish causality, and the possibility of residual confounding remains,” Dr. Spreckley said
Other limits are worth knowing. Hair loss was counted through diagnostic codes, so mild cases that never prompted an appointment simply don’t exist in the data
The researchers had no way to measure severity, or how long it lasted, or whether hair returned after stopping treatment
Additionally, the records came from just one regional health system, and every patient had type 2 diabetes – leaving the far larger group now taking these drugs purely for weight loss as an open question
Still, none of this means anyone should stop taking anything. “For many people, those benefits are likely to outweigh this relatively small potential risk,” Spreckley said
Even so, if you’re the one standing over the drain doing the math, “statistically small” is not especially comforting
Perhaps the most useful part of this study is simply that your doctor now has a reason to bring it up before you do
The study is published in the journal The BMJ
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com
—–
